Sangamo Therapeutics’ Q4 2024 Earnings Call: Insights from the Industry Leader in Gene Therapy
On March 17, 2025, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) held its Fourth Quarter and Full Year 2024 Earnings Conference Call. The call, which was open to investors and analysts, was hosted by the company’s executive team: Louise Wilkie, Vice President of Investor Relations and Corporate Communications; Sandy Macrae, Chief Executive Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Prathyusha Duraibabu, Chief Financial Officer. The call was moderated by an operator, and participants included Luis Santos from H.C. Wainwright, Maury Raycroft from Jefferies, Nicole Germino from Truist, and Gena Wang from Barclays.
Financial Highlights
During the call, the Sangamo team provided an update on the company’s financial performance for the fourth quarter and full year 2024. They reported a net loss of $145.5 million for the quarter, which was a decrease from the net loss of $159.8 million reported in the same period the previous year. For the full year, the net loss was $529.3 million, which was an improvement from the net loss of $627.1 million in 2023.
Clinical Developments
The conversation then turned to clinical developments. The team highlighted the progress of their lead program, SB-525, a gene therapy for hemophilia A. They announced that the data from the phase 3 HOPE-B study, which will be presented at an upcoming medical conference, shows that SB-525 significantly reduces the annualized bleed rate compared to the current standard of care. This is a major step forward in the development of gene therapies for hemophilia, and investors were excited about the potential for this treatment to reach the market.
Collaborations and Partnerships
Sangamo also discussed their collaborations and partnerships. They announced a new agreement with Novartis to develop gene therapies for rare genetic diseases. This partnership is expected to bring in significant revenue for Sangamo and further solidifies their position as a leader in the gene therapy industry.
Impact on Individuals
For individuals with hemophilia A, the progress of SB-525 is a promising development. This gene therapy has the potential to reduce the need for frequent infusions of clotting factor, which can be time-consuming and expensive. It could also provide a more normal life for those with hemophilia, allowing them to engage in activities that might otherwise be risky due to the fear of bleeding.
Impact on the World
The advancement of gene therapies like SB-525 has the potential to revolutionize the way we treat genetic diseases. This technology could not only provide effective treatments for conditions that currently have no cure, but it could also reduce the burden on healthcare systems and improve overall quality of life for affected individuals. Furthermore, the partnership between Sangamo and Novartis could lead to the development of gene therapies for other rare genetic diseases, further expanding the impact of this technology.
Conclusion
The Sangamo Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call provided valuable insights into the company’s financial performance and clinical developments. The progress of SB-525, a gene therapy for hemophilia A, is a major step forward in the field of gene therapy and has the potential to significantly impact the lives of individuals with this condition. Further collaborations and partnerships, such as the one with Novartis, could lead to the development of gene therapies for other rare genetic diseases and further solidify Sangamo’s position as a leader in the industry.
- Sangamo Therapeutics reported improved financial performance in Q4 2024 and FY 2024
- The progress of SB-525, a gene therapy for hemophilia A, is a major step forward in the field of gene therapy
- Sangamo announced a new partnership with Novartis to develop gene therapies for rare genetic diseases
- The impact of these developments on individuals with hemophilia A and the gene therapy industry as a whole is significant
